October 23, 2016 8:35 AM ET

Professional Services

Company Overview of Muscular Dystrophy Association, Inc.

Company Overview


3300 East Sunrise Drive

Tucson, AZ 85718

United States

Founded in 1950





Key Executives for Muscular Dystrophy Association, Inc.

Vice President
National Vice President
National Vice President
National Vice President
National Vice President
Age: 57
Compensation as of Fiscal Year 2016.

Muscular Dystrophy Association, Inc. Key Developments

Muscular Dystrophy Association to Collaborate with Catabasis Pharmaceuticals on Development of CAT-1004

Catabasis Pharmaceuticals, Inc. and the Muscular Dystrophy Association (MDA) announced a collaboration to support the Part B portion of the MoveDMD clinical trial of CAT-1004, a novel product candidate for the treatment of patients with Duchenne muscular dystrophy (DMD). Under the collaboration, MDA will provide funding for transportation to participants who need to travel to take part in the study. Part A of the MoveDMD trial has completed and Catabasis recently reported positive top-line results for safety, tolerability and pharmacokinetics. Part B of the trial is expected to initiate in the first half of 2016. The boys in Part A of the trial will be asked to participate in Part B and additional participants will also be enrolled. Catabasis is currently identifying additional patients who are interested in participating in Part B of the trial. Enrollment criteria for Part B are expected to be similar to those for Part A. The incidence of DMD in the U.S. population is estimated to be between one in every 3,500 to one in 6,000 male births. The loss of a key muscle protein called dystrophin causes muscle wasting and weakness, eventually leading to the loss of ambulation, difficulty breathing, and heart failure. Life expectancy is currently the mid- to late 20s. CAT-1004 is an oral small-molecule that Catabasis believes has the potential to be a disease-modifying therapy for the treatment of Duchenne, regardless of the underlying dystrophin mutation. CAT-1004 is an inhibitor of NF-kB, a protein that is chronically activated in DMD as well as multiple other skeletal muscle disorders. In animal models of DMD, CAT-1004 inhibited NF-kB, reduced muscle degeneration and increased muscle regeneration.

Similar Private Companies By Industry

Company Name Region
1-2-3 Payroll & HR Services, Inc. United States
123College.com, Inc. United States
13D Research LLC United States
151 Ventures, LLC United States
1790 Analytics, LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Muscular Dystrophy Association, Inc., please visit www.mdausa.org. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.